AR034226A2 - Procedimiento perfeccionado para estabilizar proteinas. - Google Patents

Procedimiento perfeccionado para estabilizar proteinas.

Info

Publication number
AR034226A2
AR034226A2 ARP020101691A ARP020101691A AR034226A2 AR 034226 A2 AR034226 A2 AR 034226A2 AR P020101691 A ARP020101691 A AR P020101691A AR P020101691 A ARP020101691 A AR P020101691A AR 034226 A2 AR034226 A2 AR 034226A2
Authority
AR
Argentina
Prior art keywords
protein
compartments
solution
stabilize proteins
buffered
Prior art date
Application number
ARP020101691A
Other languages
English (en)
Original Assignee
Boehringer Mannheim Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26145913&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AR034226(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Boehringer Mannheim Gmbh filed Critical Boehringer Mannheim Gmbh
Publication of AR034226A2 publication Critical patent/AR034226A2/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/96—Stabilising an enzyme by forming an adduct or a composition; Forming enzyme conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S435/00—Chemistry: molecular biology and microbiology
    • Y10S435/963—Methods of stopping an enzyme reaction or stabilizing the test materials

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Microbiology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Inorganic Chemistry (AREA)
  • Dermatology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Mycology (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)

Abstract

Un procedimiento perfeccionado para prevenir la formación de agregados de proteína de un liofilizado reconstituido de una composición farmacéutica de una proteína, en el cual una solución acuosa tamponada de la proteína se congela, se descongela, se divide en compartimientos de cantidades inyectables y dichos compartimientos se liofilizan, y el cual se caracteriza porque la solución acuosa tamponada de la proteína contiene tampón de fosfato de potasio como sustancia tampón y la relación de iones potasio a iones sodio en la solución es como mínimo de 10:1, puede emplearse ventajosamente para producir liofilizados estables de composiciones farmacéuticas.
ARP020101691A 1997-11-22 2002-05-09 Procedimiento perfeccionado para estabilizar proteinas. AR034226A2 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP97120528 1997-11-22
EP98102846 1998-02-19

Publications (1)

Publication Number Publication Date
AR034226A2 true AR034226A2 (es) 2004-02-04

Family

ID=26145913

Family Applications (2)

Application Number Title Priority Date Filing Date
ARP980105921A AR018020A1 (es) 1997-11-22 1998-11-20 Procedimiento perfeccionado para estabilizar proteinas particularmente anticuerpos, su almacenamiento y reconstitucion
ARP020101691A AR034226A2 (es) 1997-11-22 2002-05-09 Procedimiento perfeccionado para estabilizar proteinas.

Family Applications Before (1)

Application Number Title Priority Date Filing Date
ARP980105921A AR018020A1 (es) 1997-11-22 1998-11-20 Procedimiento perfeccionado para estabilizar proteinas particularmente anticuerpos, su almacenamiento y reconstitucion

Country Status (16)

Country Link
US (1) US6238664B1 (es)
EP (1) EP0917879B1 (es)
JP (1) JP3105494B2 (es)
KR (1) KR100315908B1 (es)
CN (1) CN1220270A (es)
AR (2) AR018020A1 (es)
AT (1) ATE220558T1 (es)
AU (1) AU714264B2 (es)
BR (1) BRPI9805021B8 (es)
CA (1) CA2254145C (es)
DE (1) DE59804785D1 (es)
DK (1) DK0917879T3 (es)
ES (1) ES2179414T3 (es)
PT (1) PT917879E (es)
TR (1) TR199802394A2 (es)
ZA (1) ZA9810650B (es)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW570805B (en) 1998-09-01 2004-01-11 Hoffmann La Roche Water-soluble pharmaceutical composition in an ionic complex
US20030118598A1 (en) * 2000-02-08 2003-06-26 Allergan, Inc. Clostridial toxin pharmaceutical compositions
US7780967B2 (en) * 2000-02-08 2010-08-24 Allergan, Inc. Reduced toxicity Clostridial toxin pharmaceutical compositions
US8632785B2 (en) * 2000-02-08 2014-01-21 Allergan, Inc. Clostridial toxin pharmaceutical composition containing a gelatin fragment
DK1398038T4 (da) * 2000-02-08 2011-03-28 Allergan Inc Lægemidler med botulinustoxin
US20060269575A1 (en) * 2000-02-08 2006-11-30 Allergan, Inc. Botulinum toxin pharmaceutical compositions formulated with recombinant albumin
DE10149030A1 (de) * 2001-10-05 2003-04-10 Viscum Ag Stabile galenische gefriergetrocknete Arzneimittelzubereitung von rViscumin
US20040185040A1 (en) * 2001-11-21 2004-09-23 Celltech R & D Limited Modulating immune responses
US20030175827A1 (en) * 2002-03-14 2003-09-18 Stillman Brett A. Stable thin film dried protein composition or device and related methods
US20040033228A1 (en) 2002-08-16 2004-02-19 Hans-Juergen Krause Formulation of human antibodies for treating TNF-alpha associated disorders
KR101235507B1 (ko) 2003-02-28 2013-02-20 추가이 세이야쿠 가부시키가이샤 단백질을 함유하는 안정화 제제
WO2007016562A2 (en) * 2005-07-29 2007-02-08 Amgen Inc. Formulations that inhibit protein aggregation
EP2076287A2 (en) * 2006-10-12 2009-07-08 Wyeth Methods and compositions with reduced opalescence
JP2012530721A (ja) * 2009-06-18 2012-12-06 ワイス・エルエルシー 小モジュール免疫薬のための凍結乾燥製剤
PE20150964A1 (es) 2012-09-07 2015-07-25 Coherus Biosciences Inc Formulaciones acuosas estables de adalimumab
BR112017006533A2 (pt) * 2014-09-29 2017-12-19 Cook General Biotechnology Llc usos de trealose em suspensões celulares
US11229702B1 (en) 2015-10-28 2022-01-25 Coherus Biosciences, Inc. High concentration formulations of adalimumab
US11071782B2 (en) 2016-04-20 2021-07-27 Coherus Biosciences, Inc. Method of filling a container with no headspace
WO2018119142A1 (en) 2016-12-21 2018-06-28 Amgen Inc. Anti-tnf alpha antibody formulations
US11110063B2 (en) 2017-08-25 2021-09-07 MAIA Pharmaceuticals, Inc. Storage stable sincalide formulations
AU2021267900A1 (en) 2020-05-08 2023-01-19 Gallant Pet Inc. Uterine-derived regenerative cell compositions and uses thereof
CN111781345A (zh) * 2020-06-30 2020-10-16 上海透景生命科技股份有限公司 化学发光标记物标记抗原稳定剂及其应用

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2652636A1 (de) 1976-11-19 1978-05-24 Hans Uwe Dr Rer Nat Wolf Verfahren zur stabilisierung von proteinen und verwandten verbindungen waehrend ihrer reinigung, isolierung und lagerung
US4783441A (en) 1979-04-30 1988-11-08 Hoechst Aktiengesellschaft Aqueous protein solutions stable to denaturation
DE3064888D1 (en) 1979-04-30 1983-10-27 Hoechst Ag Aqueous solutions of proteins stable against denaturization, process for their manufacture, and their utilization
US4362661A (en) 1979-08-09 1982-12-07 Teijin Limited Immunoglobulin composition having a high monomer content, and process for production thereof
CA1329760C (en) 1987-10-29 1994-05-24 Ted C. K. Lee Plasma and recombinant protein formulations in high ionic strength media
GB8726136D0 (en) * 1987-11-07 1987-12-09 Wellcome Found Therapeutic nucleosides
US4877608A (en) 1987-11-09 1989-10-31 Rorer Pharmaceutical Corporation Pharmaceutical plasma protein formulations in low ionic strength media
DE3863908D1 (de) 1987-11-27 1991-08-29 Akzo Nv Stabilisierung von antikoerpern.
GB8920534D0 (en) * 1989-09-11 1989-10-25 Wellcome Found Antiviral compounds
US5164296A (en) * 1990-08-31 1992-11-17 University Of Maryland At Baltimore Assay methods involving ouabain
DE4126983A1 (de) * 1991-08-15 1993-02-18 Boehringer Mannheim Gmbh Verfahren zur herstellung von humanprotein-enthaltenden, konservierten arzneimitteln fuer infusions- oder injektionszwecke
GB9401447D0 (en) 1994-01-26 1994-03-23 Ciba Geigy Ag Pharmaceutical compositions
RU2109290C1 (ru) * 1996-04-09 1998-04-20 Государственный научный центр вирусологии и биотехнологии "Вектор" Стабилизирующий состав для получения лиофилизированных препаратов на основе конъюгата антииммуноглобулина g и пероксидазы хрена
EP0852951A1 (de) * 1996-11-19 1998-07-15 Roche Diagnostics GmbH Stabile lyophilisierte pharmazeutische Zubereitungen von mono- oder polyklonalen Antikörpern

Also Published As

Publication number Publication date
BRPI9805021A (pt) 2000-03-21
EP0917879A2 (de) 1999-05-26
DK0917879T3 (da) 2002-11-04
EP0917879A3 (de) 1999-06-09
ES2179414T3 (es) 2003-01-16
ATE220558T1 (de) 2002-08-15
CA2254145C (en) 2002-10-08
TR199802394A3 (tr) 1999-06-21
KR19990045460A (ko) 1999-06-25
BRPI9805021B8 (pt) 2021-07-06
DE59804785D1 (de) 2002-08-22
BRPI9805021B1 (pt) 2011-05-31
CN1220270A (zh) 1999-06-23
AU714264B2 (en) 1999-12-23
EP0917879B1 (de) 2002-07-17
US6238664B1 (en) 2001-05-29
PT917879E (pt) 2002-12-31
JP3105494B2 (ja) 2000-10-30
JPH11240895A (ja) 1999-09-07
ZA9810650B (en) 1999-05-24
TR199802394A2 (xx) 1999-06-21
KR100315908B1 (ko) 2002-04-24
AR018020A1 (es) 2001-10-31
AU9406098A (en) 1999-06-10
CA2254145A1 (en) 1999-05-22

Similar Documents

Publication Publication Date Title
AR034226A2 (es) Procedimiento perfeccionado para estabilizar proteinas.
AR012540A1 (es) COMPOSICIoN FARMACÉUTICA LIOFILIZADA DE ANTICUERPOS MONOCLONALES O POLICLONALES, PROCEDIMIENTO PARA SU PRODUCCIoN
ES2178000T3 (es) Composiciones y metodos para tratar infecciones usando analogos de indolicidina.
EA200100337A1 (ru) Стабильные жидкие составы ботулинического токсина
EA199800563A1 (ru) Антагонисты гормона, высвобождающего гонадотропин
BR9811094A (pt) Agente terapêutico para tumores linfáticos
ES2032194T3 (es) Solubilizacion de agregados proteicos.
NO971889L (no) Forbindelser og sammensetninger for levering av aktive midler
ATE230277T1 (de) Stabilisierte antikörperformulierung
NO883926D0 (no) Fremgangsmaate for fremstilling av stabilisert humanproteinpreparat.
PT877602E (pt) Processo para o fabrico de composicoes de surfactantes pulmonares em po
PT762897E (pt) Metodo de prevencao da agregacao de proteinas/peptidos por re-hidratacao ou descongelacao
CY1106403T1 (el) Μεθοδος για την παραγωγη μιας συριγγας μιας δοσης, που πepιλαμβανει μια ξηρανθεισα μεσω ψυξης συνθεση πρωτεϊνης, για τη χορηγηση ενος ογκου λιγοτepου απο 0,5 ml
EA200200396A1 (ru) Фармацевтические композиции фибринолитического агента
MX9401211A (es) Composicion y procedimiento para combatir la aglomeracion de abonos.
EA199900876A1 (ru) Фармацевтические композиции против кашля
EP0203649A3 (en) Pharmaceutic composition based on diphoshonates for the treatment of the arthrosis
ES2095846T3 (es) Composicion estable y liofilizada de un ester/eter de polihematoporfirina.
TR200002543T2 (tr) Fosfolipaz önleyici sodyum [[3-(2-amino-1,2-dioksietil-1-fenilmetil) -2-etil-1-fenilmetil)- 1H-indol-4-il]oksi] asetat içeren farmasötik kompozisyonlar
RU2000116647A (ru) Однодозовый шприц, содержащий композицию лиофилизованного белка, для введения объема менее, чем 0,5 мл
ES2053131T3 (es) Composiciones terapeuticas para el tratamiento o la prevencion del ronquido.
ES8608542A1 (es) Un metodo para producir una composicion de gamma-interferon de ser humano.
KR860006982A (ko) 안정한 감마 인터페론 제형의 제조방법
EA200200211A1 (ru) Фармацевтическая композиция и ее приготовление
ES2056149T3 (es) Ambliommina, una nueva sustancia activa para la terapia anticoagulante.

Legal Events

Date Code Title Description
FC Refusal